Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672604 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects
A Phase 1 study, sponsored by Neuraly.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT03672604 is a Phase 1 study that has completed, run by Neuraly. The registered enrollment target is 96 participants.
The verdict
NCT03672604, a Phase 1 study, has completed, sponsored by Neuraly.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human study designed to assess the safety, tolerability, and pharmacokinetics of NLY01, a PEGylated form of exenatide, in healthy volunteers. NLY01 is being developed as a potential treatment for neurodegenerative disorders including Parkinson's disease. This study is intended to identify the appropriate dose-range for evaluation in Parkinson's disease patients.
Interventions
- DRUG NLY01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2019-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03672604
The ClinicalTrials.gov registry entry for NCT03672604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuraly, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NLY01 is the first listed.
NCT03672604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03672604 about?
NCT03672604 is a clinical study titled "A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects". This is a Phase 1, first-in-human study designed to assess the safety, tolerability, and pharmacokinetics of NLY01, a PEGylated form of exenatide, in healthy volunteers. NLY01 is being developed as a potential treatment for neurodegenerative disorders including Parkinson's disease. This study is int...
What is the current status of trial NCT03672604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2018-09-19. Estimated completion is 2019-07-30.
What interventions are being tested in trial NCT03672604?
The interventions under investigation include: NLY01 (DRUG).
Who is sponsoring clinical trial NCT03672604?
This trial is sponsored by Neuraly, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.